Анализ эффективности терапии варфарином и ривароксабаном тромбоза глубоких вен нижних конечностей в отдалённом периоде

Introduction. Effect of standard and alternative anticoagulant therapy regimens on the degree and rapidity of deep vein recana- lization attracts the attention of modern researchers. Aim: to compare the treatment effectiveness of deep vein thrombosis (DVT) of lower limbs with warfarin and rivaroxaban in the long-term period. Materials and methods. The study included 94 patients with DVT of lower limbs; they were divided into 2 groups depending on the prescribed treatment regimen. The average age of 50 patients of group 1 was 44.0 ± 12.6 years, 44 patients of group 2 — 39.5 ± 11.7 years. Warfarin was prescribed to patients of group 1, rivaroxaban — to patients of group 2; treatment was prescribed for 6 months after discharge. The endpoint of observation was 4 years. Results. 18 (36%) patients from group 1 and 2 (4.5%) patients from group 2 stopped taking the anticoagulant earlier than tar- get date. Elastic compression treatment patients in both groups kept irregularly. Recurrence of venous thromboembolic com- plications in group 1 was noted in 11 (22%) cases, in group 2 — in 7 (15.9%) patients. The negative ultrasound dynamics was observed in patients of both groups: 16% of patients in group 1 and 9.1% in group 2 had lesion signs of previously unchanged veins or occlusion of a previously passable vein after thrombosis without clinic of acute venous thrombosis. Trophic disorders were identified in 1 patient in group 2 and in 1/3 of patients in group 1 by the 4th year of observation. Significant differences between the groups were obtained in favor of rivaroxaban according to such parameters as adherence to treatment and the severity of venous insufficiency. Conclusion. Unsatisfactory results of DVT treatment with standard therapy regimen require the administration of new oral anti- coagulants with the possible introduction of prophylactic regimen. REFERENCES Ansell J., Hirsh E., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physi- cians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):160S-198S. DOI: 10.1378/chest.08–0670. Nicolaides A.N., Fareed J., Kakkar A.K. et al. Prevention of ve- nous thromboembolism — International Consensus Statement. Int Angiol. 2013;32(2):111–260. Vorobyova N.M., Ermolina O.V., Balakhonova T.V. et al. Effect of long-term enoxiparin therapy on risk of recurrent venous thromboembolic complications and recanalization of throm- bosed veins. [Vliyanie prodlennoj terapii enoksiparinom na risk recidiva tromboembolicheskih oslozhnenij i rekanalizaciyu trom- birovannyh ven]. Aterotromboz. 2015;(2):39–50. (In Russ.). DOI: 10.21518/2307-1109-2015-2-39-50. Kuznetsov M.R., Sapelkin S.V., Boldin B.V. et al. Recanaliza- tion of lower-limb deep veins as an index of the effecacy of treat- ment of acute venous thrombosis. [Rekanalizaciya glubokih ven nizhnih konechnostej kak pokazatel’ effektivnosti lecheniya ost- rogo venoznogo tromboza]. Angiologiya i sosudistaya hirurgiya. 2016;22(3):82–7. (In Russ.). Kalinin R.E., Suchkov I.A., Agapov A.B. The effectiveness of the various options of anticoagulant therapy for the treatment of the patients with thrombosis of the deep veins of the lower extremi- ties in the routine clinical practice. [Effektivnost’ razlichnyh vari- antov antikoagulyantnoj terapii pri tromboze glubokih ven nizh- nih konechnostej v rutinnoj klinicheskoj praktike]. Flebologiya. 2017;11(1):21–7. DOI: 10.17116/flebo201711121–27. (In Russ.). EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboem- bolism. New Engl J Med. 2010;363(26):2499–510. DOI: 10.1056/ NEJMoa1007903. Krivoshekov E.P., Migunov I.A. Modern approach to the treatment of acute thrombosis of deep veins with rivaroxaban. [Sovremen- nyj podhod v lechenii ostrogo tromboza glubokih ven prepara- tom rivaroksaban]. Arhiv” vnutrennej mediciny. 2015;(3):75–8. (In Russ.). DOI: 10.20514/2226-6704-2015-0-3-75–78. Zabolotskikh I.B., Kirov M. Yu., Afonchikov V.S. et al. Perioperative management of patients receiving long-term antithrombotic therapy. Russian Federation of anesthesiologists and reanimatol- ogists guidelines. [Perioperacionnoe vedenie pacientov, polucha- yushchih dlitel’nuyu antitromboticheskuyu terapiyu. Klinicheskie rekomendacii Federacii anesteziologov i reanimatologov Rossii]. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2019;(1):7–19. (In Russ.). DOI: 10.20514/2226-6704-2015-0-3-75-78. 9. Saveliev V.S., Chazov E.I., Gusev E.I. et al. Russian clinical guide- lines for the diagnosis, treatment and prevention of venous throm- boembolic complications. [Rossijskie klinicheskie rekomendacii po diagnostike, lecheniyu i profilaktike venoznyh tromboembol- icheskih oslozhnenij]. Flebologiya. 2010;4(2):2–37. (In Russ.). 10. Korobeynikova A.N., Malchikova S.V. Study of adherence to the treatment of patients with atrial fibrillation in outpatient practice. [Izuchenie priverzhennosti lecheniyu pacientov s fibrillyaciej pred- serdij v ambulatornoj praktike]. Lechashchij vrach. 2017;(2):16– 9. (In Russ.). 11. McHorney С.A., Ashton V., Lalibertе F. et al. Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrilla- tion. J Am Coll Cardiol. 2017;69(11):206. DOI: 10.1016/S0735– 1097(17)33595–7. 12. Al-Khalili F., Lindstrom C., Benson L. Adherence to anticoagu- lant treatment with apixaban and rivaroxaban in a real-world set- ting. Clin Trials Regul Sci Cardiol. 2016;18:1–4. DOI: 10.1016/j. ctrsc. 2016.03.003. 13. Andriyashkin A.B., Andriyashkin B.B., Arutyunov G.P. et al. Russian clinical guidelines for the diagnosis, treatment and pre- vention of venous thromboembolic complications. [Rossijskie klinicheskie rekomendacii po diagnostike, lecheniyu i profilak- tike venoznyh tromboembolicheskih oslozhnenij]. Flebologiya. 2015;9(4):4–51. (In Russ.). Available at: http://webmed.ir- kutsk.ru/doc/pdf/pe2015.pdf.http://webmed.irkutsk.ru/doc/ pdf/pe2015.pdf. 14. Sukovatyh B.S., Sukhovatykh M.B., Perkov S.O. Treatment re- sults of the deep venous thrombosis using oral anticoagu- lants. [Rezul’taty lecheniya trombozov glubokih ven nizhnih konechnostej oral’nymi antikoagulyantami]. Annaly hirurgii. 2017;22(5):278–83. (In Russ.). DOI: 10.18821/1560-9502-2017- 22-5-278–283. 15. Shcheglov E.A., Alontseva N.N. Current study aimed to high- light extent of clot resolution in deep veins and its association with anticoagulation pattern in VTE patients. [Stepen’ rekanal- izacii glubokih ven nizhnih konechnostej v zavisimosti ot vy- brannoj skhemy antikoagulyantnoj terapii]. Hirurgiya. Zhurnal imeni N.I. Pirogova. 2017;(4):56–60. (In Russ.). DOI: 10.17116/ hirurgia2017456–60. 16. Soldatsky E. Yu., Yumin S.M., Khabazova K.R., Andriyash- kin A.V. The late results of the treatment of distal and femoral- popliteal deep venous thrombosis. [Otdalennye rezul’taty lech- eniya tromboza glubokih ven goleni i bedrenno-podkolennogo segmenta]. Flebologiya. 2014;(1):40–9. (In Russ.). 17. Prostov I.I., Katelnitsky I.I., Katelnitskaya O.V. The long-term results of treatment of thrombosis deep veins of lower extrem- ities and their complications. [Otdalennye rezul’taty lecheniya trombozov glubokih ven nizhnih konechnostej i ih oslozhnenij]. Kubanskij nauchnyj medicinskij vestnik. 2013;(4):84–6. (In Russ.). 18. Young L., Ockelford P., Milne D. et al. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombo- sis and mortality. J Thromb Haemost. 2006;4(9):1919–24. DOI: 10.1111/j.1538–7836.2006.02120.x. 19. Sukhanova G.A., Vasileva E.V., Stotskaya T.V. Method of treating subacute venous thrombosis of various localisations. [Sposob lech- eniya podostryh venoznyh trombozov razlichnoj lokalizacii]. Pat- ent RF No 2595238 ot 18.05.2015. Byul. No 23. 9 s. (In Russ.). Avail- able at: https://patents.s3.yandex.net/RU2595238C1_20160820. pdf. 20. Heit J.A., Spencer F.A., White R.H. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. DOI: 10.1007/s11239-015-1311-6.